KIDS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

59.28M

+12.55%

-0.335

-51.45%

58.77M

+12.13%

-0.432

-5.98%

68.48M

+12.1%

-0.318

+5.83%

Estimates Revision

The market is revising Downward the revenue expectations for OrthoPediatrics Corp. (KIDS) for FY2025, with the revenue forecasts being adjusted by -2.28% over the past three months. During the same period, the stock price has changed by 2.01%.

Revenue Estimates for FY2025

Revise Downward

-2.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+21.02%

In Past 3 Month

Stock Price

Go Up

+2.01%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 24.00 USD with a low forecast of 18.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

18.00

Averages

24.00

High

34.00

Current: 0.000

Low

18.00

Averages

24.00

High

34.00

Canaccord

Caitlin Roberts

initiated

$24

2025-12-10

Reason

Canaccord

Caitlin Roberts

Price Target

$24

2025-12-10

initiated

Reason

Canaccord analyst Caitlin Roberts initiated coverage of OrthoPediatrics with a Buy rating and $24 price target.

Canaccord

initiated

$24

2025-12-10

Reason

Canaccord

Price Target

$24

2025-12-10

initiated

Reason

As previously reported, Canaccord initiated coverage of OrthoPediatrics with a Buy rating and $24 price target. OrthoPediatrics has established a "strong position" in the pediatric orthopedic device market, says the analyst. The firm sees the company's recent guidance update, in which it lowered guidance for 2025 and established 12%-plus as a baseline for annualized growth, as a de-risking event that leaves room for upside.

Needham

Buy

downgrade

$42 -> $26

2025-10-29

Reason

Needham

Price Target

$42 -> $26

2025-10-29

downgrade

Buy

Reason

Needham lowered the firm's price target on OrthoPediatrics to $26 from $42 and keeps a Buy rating on the shares. The company's Q3 revenue was just above its pre-announcement and adjusted EBITDA missed consensus, the analyst tells investors in a research note. OrthoPediatrics previously indicated that it now expects revenue growth of over 12% over the next few years, and while this is conservative and leaves room for potential upside, the firm is lowering its price target given its lower revenue growth forecasts, Needham added.

Citizens JMP

David Turkaly

Outperform

downgrade

$50 -> $35

2025-08-08

Reason

Citizens JMP

David Turkaly

Price Target

$50 -> $35

2025-08-08

downgrade

Outperform

Reason

Citizens JMP analyst David Turkaly lowered the firm's price target on OrthoPediatrics to $35 from $50 and keeps an Outperform rating on the shares. OrthoPediatrics reported a quarterly record on its top line, though revenues and adjusted EBITDA were shy of consensus, but the company continues to take share in all of its key market segments, and full-year guidance was largely reiterated, the analyst tells investors in a research note. The firm believes the fundamentals around the business remain solid.

BTIG

Buy

maintain

$40 -> $39

2025-08-06

Reason

BTIG

Price Target

$40 -> $39

2025-08-06

maintain

Buy

Reason

BTIG lowered the firm's price target on OrthoPediatrics to $39 from $40 and keeps a Buy rating on the shares after its Q2 results. Trauma & Deformity - T&D - performance was soft in the quarter, but this was offset by an 11.6% beat within Scoliosis, while gross margin and operating margin missed the Street by 170bps and 720bps, the analyst tells investors in a research note.

Truist

Hold

downgrade

$26 -> $22

2025-08-06

Reason

Truist

Price Target

$26 -> $22

2025-08-06

downgrade

Hold

Reason

Truist lowered the firm's price target on OrthoPediatrics to $22 from $26 and keeps a Hold rating on the shares after its Q2 results. The firm continues to like the momentum drivers and ramping profit story for this uniquely positioned asset, but it will take more steady/larger magnitude of beats/raises to support multiple expansion, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for OrthoPediatrics Corp (KIDS.O) is -13.35, compared to its 5-year average forward P/E of -42.72. For a more detailed relative valuation and DCF analysis to assess OrthoPediatrics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-42.72

Current PE

-13.35

Overvalued PE

-22.66

Undervalued PE

-62.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

265.52

Current EV/EBITDA

19.44

Overvalued EV/EBITDA

690.57

Undervalued EV/EBITDA

-159.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.84

Current PS

1.72

Overvalued PS

9.10

Undervalued PS

2.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 114.29% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KIDS News & Events

Events Timeline

No data

News

5.0

2025-11-13Newsfilter

OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products

4.0

2025-11-09Yahoo Finance

What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?

4.0

2025-10-29Benzinga

Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations

People Also Watch

Frequently Asked Questions

What is OrthoPediatrics Corp (KIDS) stock price today?

The current price of KIDS is 18.31 USD — it has decreased -2.24 % in the last trading day.

What is OrthoPediatrics Corp (KIDS)'s business?

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.

What is the price predicton of KIDS Stock?

What is OrthoPediatrics Corp (KIDS)'s revenue for the last quarter?

OrthoPediatrics Corp revenue for the last quarter amounts to 61.25M USD, increased 12.23 % YoY.

What is OrthoPediatrics Corp (KIDS)'s earnings per share (EPS) for the last quarter?

OrthoPediatrics Corp. EPS for the last quarter amounts to -0.50 USD, increased 47.06 % YoY.

What changes have occurred in the market's expectations for OrthoPediatrics Corp (KIDS)'s fundamentals?

How many employees does OrthoPediatrics Corp (KIDS). have?

OrthoPediatrics Corp (KIDS) has 562 emplpoyees as of January 10 2026.

What is OrthoPediatrics Corp (KIDS) market cap?

Today KIDS has the market capitalization of 459.17M USD.